INTRODUCTION
============

Ulcerative colitis (UC) is a chronic disease with a relapse-remitting course. Corticosteroids are the first choice in patients with moderate-to-severe disease activity. Although corticosteroids are an effective treatment option, approximately 40% of patients are resistant to or dependent on corticosteroids.

The treatment of corticosteroid-refractory UC is challenging, and colectomy is often indicated in these patients. Cyclosporine, a calcineurin inhibitor, has been used as a salvage therapy in corticosteroid-refractory patients. Lichtiger et al. reported a randomized controlled trial on the use of cyclosporine in acute severe UC.[@B1] In this trial, 20 corticosteroid-refractory severe UC patients were randomly assigned to receive intravenous cyclosporine infusion at 4 mg/kg daily or placebo. The response rate at 7 days was 82% (9/11) in the cyclosporine group compared to 0% (0/9) in the placebo group. Intravenous cyclosporine is usually followed by oral cyclosporine, but intestinal absorption of cyclosporine is poor and unstable, and therefore, it is difficult to achieve optimal trough levels with oral cyclosporine.

Tacrolimus is a macrolide antibiotic, isolated from the soil bacterium *Streptomyces tsukubaensis*. It possesses potent immunosuppressive properties and has been used to prevent organ rejection after allogeneic organ transplantation or graft-versus-host disease after hematopoietic stem cell transplantation. The absorption of tacrolimus through the intestine is much better than that of cyclosporine. Considering these properties of tacrolimus, it is commonly used for the treatment of corticosteroid-refractory UC instead of cyclosporine. In Japan, tacrolimus was approved for clinical use in corticosteroid-refractory UC patients in 2010 and has been incorporated in the management of refractory UC. Here, we review the literature on the use of tacrolimus in UC patients.

MECHANISM OF ACTION
===================

Tacrolimus mainly exerts its immunosuppressive action by inhibiting T-cell activation and proliferation. Upon T-cell receptor activation by antigen-presenting cells, intracellular calcium concentrations increase, leading to activation of calcineurin, a calcium and calmodulin-dependent phosphatase. The transcription factor, nuclear factor of activated T-cells (NFAT) is dephosphorylated by calcineurin, and then, it moves to the nucleus and induces transcription of interleukin-2 and other related genes. interleukin-2 is essential for T-cell activation and proliferation. Tacrolimus binds to the immunophilin FK binding protein (FKBP) and forms a complex, which binds to calcineurin and inhibits its activity. The immunosuppressive properties of tacrolimus have been reported to be 100 times greater than those of cyclosporine both *in vivo* and *in vitro*.[@B2][@B3]

REMISSION INDUCTION
===================

The first case series to assess the efficacy of tacrolimus for IBD was reported in 1998.[@B4] This study included 11 corticosteroid-refractory patients (6 with UC, 2 with indeterminate colitis, 2 with CD, and 1 with pouchitis). All patients were treated with intravenous tacrolimus for 7-10 days, followed by oral tacrolimus treatment. Of the 11 patients, 7 (63.6%) achieved remission.

The first randomized double-blind controlled trial on the use of oral tacrolimus in UC patients was reported by Ogata et al. in 2006.[@B5] In this study, 60 corticosteroid-refractory UC patients were randomly assigned to receive oral tacrolimus at high serum trough (10-15 ng/mL; n=19) or low serum trough (5-10 ng/mL; n=21) levels, or placebo (n=20). At 2 weeks after treatment, the clinical response rates were 68.4% and 38.1% in the high trough and low trough groups, respectively, and 10.0% in the placebo group. Ogata et al. further examined the efficacy of oral tacrolimus in a large randomized controlled trial that included 62 patients with corticosteroid-refractory, moderate-to-severe UC.[@B6] In this study, the serum trough levels were fixed at 10-15 ng/mL in the tacrolimus group. A result similar to that of the first study was obtained, with clinical response rates of 50.0% in the tacrolimus group and 13.3% in the placebo group. Presently, these studies are the only controlled trials on the efficacy of tacrolimus in UC patients.

Many retrospective cohort studies have examined the efficacy of tacrolimus in UC patients in real-world settings[@B4][@B5][@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15][@B16][@B17][@B18][@B19][@B20][@B21] ([Table 1](#T1){ref-type="table"}). The largest study was reported from Germany, and it included 130 patients from 3 institutions.[@B15] In this study, clinical remission was achieved in 94 patients (72%). Furthermore, the authors reported that concomitant use of thiopurine significantly increased the rate of remission. Miyoshi et al. reported 51 patients who were treated with oral tacrolimus. In this study, the clinical response rate at 3 months after treatment was 62.7% (32/53; 20 patients (39.2%) in remission, 12 patients (23.5%) with improvement).[@B22]

Several retrospective studies have shown the efficacy of tacrolimus in pediatric patients. A study that included 46 pediatric patients with corticosteroid-refractory colitis showed that 93% of patients avoided immediate colectomy with tacrolimus.[@B23][@B24] Ziring et al. reported the outcomes of 18 consecutive pediatric patients who were treated with oral tacrolimus. Of the 18 patients, 17 (94.4%) responded to treatment.[@B25]

Taken together, these findings suggest that tacrolimus is an effective treatment for remission induction in corticosteroid-refractory UC patients, although evidence from controlled studies is limited.

LONG-TERM PROGNOSIS
===================

Despite the high response rates in remission induction with tacrolimus, long-term prognosis after tacrolimus treatment is disappointing. Miyoshi et al. analyzed 51 patients who were treated with tacrolimus and reported that the relapse-free survival rates were 73.0% at 6 months, 49.9% at 1 year, and 37.8% at 2 years after treatment.[@B22] Additionally, a retrospective study from 3 French referral centers demonstrated that only 27% of patients had clinical remission at 54 weeks after treatment.[@B26] Furthermore, the rates of long-term colectomy-free survival have been reported to be 56.5% at 43.8 months,[@B10] 59.3% at 2 years,[@B16] and 62.3% at 65 months after treatment.[@B12] These findings demonstrate that immediate colectomy may be avoided with tacrolimus; however, about 50.0% of patients eventually required colectomy in long-term follow-up.

A few uncontrolled studies suggested the effect of tacrolimus on remission maintenance. A study by Baumgart et al. assessed the long-term efficacy of oral low-dose tacrolimus in 40 UC patients. Of these 40 patients, 31 (77.5%) maintained remission during a mean treatment duration of 25.2 months at serum trough levels of 4-8 ng/mL.[@B10] A retrospective analysis by Yamamoto et al. showed that the long-term relapse-free survival rates of patients administered tacrolimus as remission induction therapy (n=24) were comparable to those of patients administered thiopurine (n=34).[@B27] These findings suggest that tacrolimus can be used as remission maintenance therapy. Randomized controlled studies are necessary to show the effects of long-term tacrolimus administration as remission maintenance therapy in UC patients. Additionally, studies to determine the optimal duration and trough levels for remission maintenance are required.

MUCOSAL HEALING
===============

Mucosal healing has been an emerging therapeutic target in UC treatment. In the study by Ogata et al. in 2012, the rate of mucosal healing at 12 weeks after treatment was 43.8% (14/32) in the tacrolimus group and 13.3% (4/30) in the placebo group.[@B6] Miyoshi et al. reported the endoscopic results of 36 patients who received oral tacrolimus treatment and underwent colonoscopy after 3 months of treatment. Of these 36 patients, 12 (33.3%) and 10 (27.8%) showed Mayo endoscopic scores of 0 and 1, respectively.[@B22] Furthermore, patients with a Mayo endoscopic score of 0 or 1 had a significantly better medium-to-long term prognosis compared to that in those with a score of 3 or 4. Additionally, Ikeya et al. reported that the rate of mucosal healing was 43.8% (14/32) in patients treated with tacrolimus and that mucosal healing was associated with a favorable prognosis.[@B21] These findings confirm that mucosal healing can be achieved with tacrolimus and may be used as a therapeutic target of this treatment.

TACROLIMUS VERSUS ANTI-TUMOR NECROSIS FACTOR (TNF)-ALPHA ANTIBODY THERAPY
=========================================================================

Anti-TNF-α antibody therapy is an option for the treatment of corticosteroid-refractory UC.[@B28][@B29] Thus far, no direct comparative studies have assessed the efficacy of tacrolimus and anti-TNF-α antibody therapy in UC patients. A randomized, prospective head-to-head comparative study of tacrolimus and infliximab in corticosteroid-refractory UC patients is being performed in Japan.

A recent randomized controlled study demonstrated that infliximab and cyclosporine, another calcineurin inhibitor, were equally effective for remission induction in corticosteroid-refractory acute severe UC patients.[@B30] Additionally, several retrospective studies have shown a similar efficacy between infliximab and cyclosporine for remission induction; however, long-term prognosis was more favorable in patients treated with infliximab than in those treated with cyclosporine.[@B31][@B32][@B33][@B34] A recent retrospective study assessed short-term outcomes in patients with severe UC treated with tacrolimus (n=22) or infliximab (n=7).[@B35] The rates of clinical remission were 63.6% and 71.4% in the tacrolimus and infliximab groups, respectively.

These findings suggest that the therapeutic effect of calcineurin inhibitors is comparable to that of infliximab in terms of remission induction. However, the mechanisms of action of these drugs are completely different. Therefore, it is important to select an appropriate therapy in each patient. Additionally, the optimization of remission maintenance therapy is challenging after calcineurin inhibitor therapy.

SWITCHING BETWEEN TACROLIMUS AND ANTI-TNF-ALPHA ANTIBODY THERAPY
================================================================

Three studies have used infliximab as rescue therapy in patients who were refractory to tacrolimus, and the shortterm response rates were 25.0% (6/24),[@B36] 46.2% (6/13),[@B37] and 50.0% (6/12) in these studies.[@B38] Yamamoto et al. further showed that the rate of colectomy-free survival was 58.3% at 41.4 months after treatment.[@B38] Conversely, Boschetti et al. evaluated the efficacy of tacrolimus in 30 patients who were refractory to anti-TNF-α antibody therapy.[@B26] In this study, clinical response was observed in 21 patients (70%) at 4 weeks after treatment, with 14 patients (47%) in clinical remission, and 8 patients (27%) maintained clinical remission at 52 weeks after treatment. These findings suggest that switching between tacrolimus and anti-TNF-α antibody therapy may be an effective therapeutic option in selected patients. However, evidence on long-term prognosis is scarce.

Attention should be paid to the risk of opportunistic infections when switching between 2 immunosuppressive agents.[@B39] Additionally, there is a concern that the use of multiple immunosuppressive agents increases perioperative complications. Saito et al. reported that the frequency of postoperative complications did not increase in patients who underwent colectomy after receiving multiple immunosuppressive agents compared to that in patients who underwent colectomy after receiving only 1 immunosuppressive agent.[@B40] The benefits and risks should be carefully considered when switching between a calcineurin inhibitor and anti-TNF-α antibody therapy.

BLOOD TROUGH LEVELS
===================

The therapeutic effect of tacrolimus appears to depend on the trough level. In the study by Ogata et al. in 2006, the clinical response rate was higher in the high trough (10-15 ng/mL) group than in the low trough (5-10 ng/mL) group.[@B5] Additionally, the study by Ogata et al. in 2012 showed that continuation of tacrolimus at a low trough level (5-10 ng/mL) until 12 weeks increased the rate of mucosal healing from 66.7% (14/21) to 85.7% (18/21) and that of clinical remission from 14.3% (3/21) to 28.6% (6/21).[@B6] Based on these findings, the standard target trough level in Japan is 10-15 ng/mL for 2 weeks, followed by 5-10 ng/mL for 12 weeks. However, for long-term use of tacrolimus, the optimal trough level has not yet been determined.

Several factors affect the blood trough levels of tacrolimus. First, fasting affects the pharmacokinetics of tacrolimus. C~max~ is almost 4 times higher in a fasting condition than in a fed condition.[@B41] Second, genetic backgrounds can affect the blood trough levels of tacrolimus. Tacrolimus is metabolized predominantly by cytochrome P-450 (CYP) 3A4 and 3A5 enzymes, and is a substrate for the drug efflux pump Pglycoprotein encoded by the *ABCB1* gene. A German study reported that the short-term response to tacrolimus was associated with homozygous variants for 1 of the 3 *ABCB1* alleles, but not with *CYP3A5* polymorphisms.[@B14] Interestingly, a Japanese study reported opposite results. Hirai et al. examined the expression of *CYP3A5* in 45 patients treated with tacrolimus.[@B19] Of these 45 patients, 24 (53.3%) were *CYP3A5* expressers and 21 (46.7%) were non-expressers. The trough levels at 2-5 days after treatment were significantly higher in the *CYP3A5* expressers than in the non-expressers. This rapid increase in trough levels was associated with a higher rate of remission in the non-expressers (47.6%) than in the expressers (16.7%). *ABCB1* gene polymorphisms were not associated with trough levels. These findings suggest a genetic difference between Asian and Caucasian populations in tacrolimus metabolism.

ROUTE OF ADMINISTRATION
=======================

Both oral and intravenous formulas are available in tacrolimus treatment. The oral formula is often used for the treatment of UC, because tacrolimus is efficiently absorbed from the intestine.

Fellermann et al. compared intravenous administration of tacrolimus with oral administration in 38 patients with colitis (33 with UC and 5 with indeterminate colitis).[@B7] In this study, tacrolimus was administered intravenously at a dose of 0.01-0.02 mg/kg in 18 patients for up to 14 days, followed by oral administration. Additionally, it was administered orally at a dose of 0.1-0.2 mg/kg in 20 patients. The efficacy was similar between the intravenous and oral groups in terms of the rates of response, remission, and colectomy. Additionally, blood tacrolimus levels were comparable between the 2 groups. In our experience, response rates are similar in patients treated with tacrolimus intravenously and those treated orally. However, target blood levels can be achieved within a few days with intravenous infusion, while it takes 4-5 days to reach target blood trough levels with oral administration (unpublished data). Thus, the therapeutic response can be determined earlier in intravenously treated patients than in orally treated patients, and this earlier decision can be critical in severely ill patients.

Rectal administration of tacrolimus may be effective in patients with left-sided colitis or proctitis, because tacrolimus ointment is used to treat atopic dermatitis. A study examined the efficacy of tacrolimus enema or suppository in distal colitis.[@B42] The enema and suppository contained 2-4 mg and 2 mg of tacrolimus, respectively. After treatment for 4 weeks, 13 of 19 patients (68.4%) showed clinical improvement. Additionally, a small prospective study demonstrated that 6 of 8 patients with refractory distal colitis achieved remission with rectal tacrolimus administration.[@B43] Uchino et al. used tacrolimus enema in 10 patients with antibiotic-refractory pouchitis.[@B44] In this study, clinical symptoms improved in 9 patients (90.0%) after 8 weeks of treatment. Based on these findings, rectal tacrolimus treatment may be effective and should be examined in future randomized controlled studies.

ADVERSE EVENTS
==============

A systematic review examining tacrolimus use in UC patients reported that the most frequently observed adverse events were neurotoxicity, including tremor and headache, followed by gastrointestinal disorders, nephrotoxicity, and metabolic disorders.[@B45] Most of the adverse events were mild, and could be attenuated by reducing the dose of tacrolimus. Opportunistic infections, especially pneumocystis pneumonia, are the most important adverse events, and these should be carefully considered during tacrolimus treatment.[@B46] Prophylaxis for pneumocystis pneumonia and its close monitoring should be considered in patients treated with tacrolimus.

Safety data on the long-term administration of tacrolimus in UC patients are limited. Baumgart et al. reported on 53 IBD patients (40 with UC, 11 with CD, and 2 with pouchitis) who were treated with tacrolimus for a mean of 25.2 months.[@B10] In this study, the most common adverse events were tremor and paresthesia (n=5, 9.4%), followed by a temporal rise in serum creatinine levels (n=4, 7.6%). Nephrotoxicity may be a limiting factor for the long-term use of tacrolimus.

CONCLUSIONS
===========

Tacrolimus shows excellent efficacy for remission induction in corticosteroid-refractory UC patients. However, several questions remain unanswered: (1) Can tacrolimus be used as maintenance therapy? (2) What is the optimal trough level for long-term use? (3) What is the optimal administration route? (4) How to determine whether to administer tacrolimus or anti-TNF-α antibody therapy? (5) Is combination therapy of low-dose tacrolimus and infliximab, which has been reported to be effective in rheumatoid arthritis patients, feasible in UC patients? More controlled studies are needed to answer these clinical questions regarding tacrolimus and optimize its use in the treatment of UC. Furthermore, the identification of predictive factors or development of biomarkers to predict therapeutic responses to tacrolimus is needed. Tacrolimus is used primarily in Japan among the Asian countries,[@B47] and it can become an indispensable treatment option for corticosteroid-refractory UC globally with further optimization of its use.
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  Reference                        Study design                       N                  Administration route   Treatment duration   Observation period   Response                              Remission                           Colectomy   Initial daily dose         Target trough level
  -------------------------------- ---------------------------------- ------------------ ---------------------- -------------------- -------------------- ------------------------------------- ----------------------------------- ----------- -------------------------- --------------------------
  Fellermann et al. (1998)[@B4]    Retro. cohort                      6                  i.v. → oral            0.25-16 mo           \-                   0 (0.0)                               4 (66.7)                            2 (33.3)    0.01-0.02 mg/kg for i.v.   \-
  0.1-0.2 mg/kg for oral                                                                                                                                                                                                                                                   
  Fellermann et al. (2002)[@B7]    Retro. cohort                      38 (incl. 5 IC)    i.v. → oral (n=18)     7.6 mo^\*^           16.2 mo^\*^          10 (26.3) at 3 mo                     13 (34.2) at 3 mo                   13 (34.2)   0.01-0.02 mg/kg for i.v.   \-
  oral (n=20)                      0.1-0.2 mg/kg for oral                                                                                                                                                                                                                  
  Hogenauer et al. (2003)[@B8]     Retro. cohort                      9                  oral                   15 wk^\*^            21 mo^\*^            2 (22.2) at 12 wk                     6 (66.7) at 12 wk                   3 (33.3)    0.15mg/kg                  10-20 ng/mL
  Baumgart et al. (2003)[@B9]      Retro. cohort                      23                 oral                   12 mo^†^             18.4 mo^†^           5 (21.7)                              17 (73.9)                           3 (13.0)    0.1 mg/kg                  4-6 ng/mL
  Ogata et al. (2006)[@B5]         RCT                                19 in HT           oral                   2 wk                 2 wk                 13 (68.4) in HT                       0 (0.0)                             0 (0.0)     0.05 mg/kg                 10-15 ng/mL in HT
  21 in LT                         8 (38.1) in LT                     5-10 ng/mL in LT                                                                                                                                                                                     
  Baumgart et al. (2006)[@B10]     Retro. cohort                      40                 oral                   25.2 mo^\*^          39 mo^\*^            13 (32.5) at 4 wk                     18 (45.0) at 4 wk                   9 (22.5)    0.1 mg/kg                  4-8 ng/mL
  Ng et al. (2007)[@B11]           Retro. cohort                      6                  oral                   5 mo^†^              8 mo^†^              1 (16.7) at 4 wk                      3 (50.0) at 4 wk                    \-          \-                         \-
  Yamamoto et al. (2008)[@B12]     Retro. cohort                      27                 oral                   11 mo^†^             17.5 mo^†^           2 (7.4) at 4 wk                       19 (70.4) at 4 wk                   7 (26.9)    0.1 mg/kg                  10-15 ng/mL → 5-10 ng/mL
  Benson et al. (2008)[@B13]       Retro. cohort                      32                 oral                   29 wk\*              92 wk^\*^            22 (68.8)                             3 (9.3)                             12 (37.5)   0.2 mg/kg                  10-12 ng/mL
  Herrlinger et al. (2011)[@B14]   Retro. cohort                      84                 oral                   6 wk                 6 wk                 12 (14.3)                             51 (60.7)                           25 (29.8)   0.1-0.2 mg/kg              10 ng/mL
  Ogata et al. (2012)[@B6]         RCT                                32                 oral                   2 wk                 2 wk                 13 (40.6)                             3 (9.3)                             0 (0.0)     2-5 mg/day                 10-15 ng/mL
  Schmidt et al. (2013)[@B15]      Retro. cohort                      130                oral                   12 wk                12 wk                \-                                    94 (72.3)                           18 (13.8)   0.1 mg/kg                  \-
  Thin et al. (2013)[@B16]         Retro. cohort                      24                 oral                   11 mo^\*^            1 yr                 12 (50.0) at 3 mo, 4 (16.7) at 1 yr   8 (33.3) at 3 mo 4 (16.7) at 1 yr   16 (66.7)   0.1 mg/kg                  8-12 ng/mL
  Mizoshita et al. (2013)[@B17]    Retro. cohort                      26                 oral                   12 wk                12 wk                14 (53.8)                             4 (15.4)                            \-          \-                         10-15 ng/mL → 5-10 ng/mL
  Landy et al. (2013)[@B18]        Retro. cohort                      25                 oral                   9 mo^†^              27 mo^†^             13 (52.0) at 6 mo                     11 (44.0) at 6 mo                   8 (32.0)    0.1 mg/kg                  5-10 ng/mL
  Hirai et al. (2014)[@B19]        Retro. cohort                      45                 oral                   4 wk                 4 wk                 \-                                    14 (31.1)                           4 (8.9)     0.1 mg/kg                  10-15 ng/mL
  Kawakami et al. (2015)[@B20]     Prospective observational cohort   49                 oral                   4 wk                 4 wk                 7 (14.3)                              37 (75.5)                           3 (6.1)     0.1 mg/kg                  10-15 ng/mL → 5-10 ng/mL
  Ikeya et al. (2015)[@B21]        Retro. cohort                      44                 oral                   51.7 wk^\*^          12 wk                9 (28.1) at 12 wk                     29 (65.9) at 12 wk                  7 (15.9)    0.1 mg/kg                  10-15 ng/mL → 5-10 ng/mL

Values are presented as n (%).

^\*^mean, ^†^median.

Retro, retrospective; i.v., intravenous; incl., including; IC, indeterminate colitis; RCT, randomized controlled trial; HT, high trough; LT, low trough.
